The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit

European Journal of Cancer Care

Volumn 19, Issue 3, 2010, Pages 403-407

  Ng, W L ^a   Della Fiorentina, S A ^a  

^a Liverpool and Macarthur Cancer Therapy Centres   (Australia)

Author keywords

Chemotherapy; Efficacy; Moderately emetogenic; Ondansetron; Oral anti emetics

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; ONDANSETRON;

ARTICLE; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; VOMITING;

ADMINISTRATION, ORAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; RETROSPECTIVE STUDIES; VOMITING;

EID: 77953143037     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01068.x     Document Type: Article

References (17)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstadt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Journal of Clinical Oncology 2006, 24:4472-4478.
2. Common Terminology Criteria for Adverse Events, Version 3.0. DCTD, NCI, NIH, DHHS. 2003, http://ctep.cancer.gov/, Cancer Therapy Evaluation Program, Available at:
3. Antiemetics, Moderate Emetogenicity, Pre-chemotherapy Medications. Cancer Institute NSW. 2006, https://www.treatment.cancerinstitute.org.au, CI-SCaT (Standard Cancer Treatment Program), Available at:
4. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medial Practitioners. Australian Government Department of Health and Ageing 2007. 2007, http://www.pbs.gov.au/html/home, Commonwealth of Australia, Available at:
5. Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N, Stiff P. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biology of Blood and Marrow Transplantation 2001, 7:597-603.
6. Gralla RJ. New agents, new treatment, and antiemetic therapy. Seminars in Oncology 2002, 29:119-124.
7. Gralla RJ, Lichinitser M, Van der Vegt S, Sleebom H, Mezger J, Peschel C, Tonini G, Labianca R, Macchiocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Annals of Oncology 2003, 14:1570-1577.
8. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology 2006, 24:2932-2947.
9. McCune JS, Oertel MD, Pfeifer D, Houston SA, Bingham A, Sawyer WT, Lindley CM. Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study. The Annals of Pharmacotherapy 2001, 35:1-14.
10. Abbreviated Prescribing Information: Ondansetron hydrochoride. 2007, http://www.mims.com.au, MIMS Online, Available at:
11. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life: the quality of life and symptom control committees of the national cancer institute of Canada clinical trials group. Supportive Care in Cancer 1997, 5:307-313.
12. Perez EA, Hesketh PJ, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. Journal of Clinical Oncology 1998, 16:754-760.
13. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MaG, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003, 97:3090-3098.
14. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of Oncology 2006, 17:20-28.
15. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist 2003, 8:187-198.
16. Stewart A, McQuade B, Cronje JD, Goedhals L, Gudgeon A, Corette L, Froger X, Tubiana-Hulin M, Laplaige P, Roberts JT. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients. Oncology 1995, 52:202-210.
17. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Journal of Clinical Oncology 2005, 23:2822-2830.